Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

July 2013

Update on Tecfidera (dimethyl fumarate) Capsules 


The U.S. Food and Drug Administration (FDA) approved Tecfidera (dimethyl fumarate) capsules for the treatment of adults with relapsing forms of multiple sclerosis. Tecfidera is covered under the pharmacy benefit at Tier 3 (Tier 4 for 4-tier formulary members) through Harvard Pilgrim’s specialty pharmacy program and is available at Curascript Pharmacy. For more information, visit Harvard Pilgrim’s pharmacy page.

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Childhood Obesity Conference in September

Children and Media Survey for Clinicians

Medicare Advantage Product Available in 2014

CLINICIAN CORNER

Update on Tecfidera (dimethyl fumarate) Capsules

Reminder: Compounded Prescriptions Benefit Change

Recognizing Stress in the Primary Care Setting

Vaccine Information and Resources for Clinicians

OFFICE ASSISTANT

Reimbursement for Ambulatory Infusion Pumps

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Joann Peck,
Manager, Network Planning and Administration

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator